Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic RNA

A technology of identity and composition, applied in gene therapy, DNA preparation, recombinant DNA technology, etc., can solve problems such as difficult to treat and low long-term survival rate

Pending Publication Date: 2019-10-15
SANOFI SA
View PDF15 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Solid tumors that are resistant to or relapse after multiple therapies are even more difficult to treat and have a long-term survival rate of less than 10%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic RNA
  • Therapeutic RNA
  • Therapeutic RNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-

[0928] Example 1 - Materials and methods

[0929] B16F10 Tumor Model: Female C57BL / 6J mice (Jackson Laboratory; Bar Harbor, ME) aged 6 to 8 weeks and weighing between 17.0 and 20.9 g were acclimatized for at least three days prior to study participation. Mice had ad libitum access to chow (Harlan 2916 rodent chow, Massachusetts, USA) and sterile water, and were housed on a 12-hour light / dark cycle at 22°C±2°C and 55%±15% relative humidity. B16F10 cells were obtained from the American Type Culture Collection (ATCC) (Manassas, Virginia USA) (catalogue number CRL-6475), and were supplemented with 10% heat-inactivated fetal bovine serum (HI FBS) (Life technologies, Cat. No. 10082-147) in Dulbecco's Modified Eagle's Medium (DMEM) (Life technologies, Cat. No. 11995) in 5% CO 2 , Culture at 37°C. Cells were harvested using 0.25% trypsin-EDTA (Life technologies, Cat. No. 25200-056), resuspended in Dulbecco's Phosphate Buffered Saline (DPBS) (Life technologies, Cat. No. 14190-144), a...

Embodiment 2

[0959] Example 2 - Combination of three mRNAs reduces tumor volume in vivo

[0960] A mixture of modified mRNAs encoding GM-CSF, IL-2 and IL-12sc was injected into B16F10 tumor bearing mice and tumor growth was monitored until day 41. As shown in Figure 1, three mRNAs with ModA encoding GM-CSF, IL-2 and IL-12sc (SEQ ID NO: 32, 38 and 56; Figure 1A ), or three mRNAs with ModB encoding GM-CSF, IL-2 and IL-12sc (SEQ ID NOs: 35, 41 and 59; Figure 1B ), induced regression in 6 / 10 mice, whereas mice treated with control mRNA (ModA) encoding luciferase showed tumor regression in 1 / 10 animals ( Figure 1C ). These data were confirmed in a replicate study of a similar design ( Figure 1D to Figure 1G ). In repeated experiments, a mixture of cytokine mRNAs (GM-CSF, IL-2, IL-12sc) with ModA or ModB produced tumor regression in 5 / 9 mice, while treatment with control mRNAs in ModA and ModB, respectively 2 / 9 and 0 / 9 tumor regressions were consistently demonstrated.

[0961] The effe...

Embodiment 3

[0964] Example 3 - Combination of four mRNAs reduces tumor volume in vivo

[0965] Next, we tested the effect of adding a fourth mRNA to the cytokine mRNA mix. B16F10 tumor bearing mice received four intratumoral injections of the ModB cytokine mRNA cocktail encoding: i) GM-CSF, IL-2, IL-12sc (SEQ ID NOS: 59, 35 and 41; Figure 5A ), ii) GM-CSF, IL-15sushi, IL-12sc (SEQ ID NO:59, 53 and 41; Figure 5B ) and iii) GM-CSF, IL-15sushi, IL-12sc, IFNα (SEQ ID NOs: 59, 53, 41 and 47; Figure 5C ); and tumor growth was monitored until day 45. Each of the cytokine mRNA mixtures has an antitumor effect after intratumoral injection of GM-CSF, IL-2 and IL-12sc or the cytokine mRNA mixture of GM-CSF, IL-15sushi and IL-12sc, of which 4 / 8 tumors regressed; and 7 / 8 tumors regressed after treatment with GM-CSF, IL-15sushi, IL-12sc and IFNα. Mice treated with control mRNA (ModB) did not exhibit tumor regression ( Figure 5D ).

[0966] The antitumor activity of GM-CSF, IL-2, IL-12sc and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to the field of therapeutic RNAs for treatment of solid tumor cancers.

Description

technical field [0001] This application claims U.S. Provisional Application No. 62 / 464,981, filed February 28, 2017, U.S. Provisional Application No. 62 / 597,527, filed December 12, 2017, and European Patent Application No. 17306089.8, filed August 23, 2017 priority, all documents are incorporated by reference in their entirety. Background technique [0002] The present invention relates to the field of therapeutic RNAs for the treatment of solid tumors. The National Cancer Institute defines solid tumors as abnormal masses of tissue that usually do not contain cysts or areas of fluid. Solid tumors include benign and malignant (cancerous) sarcomas, carcinomas, and lymphomas, and can be physically located in any tissue or organ, including brain, ovary, breast, colon, and others. Cancers are generally divided into two main types: solid tumor cancers and hematological (blood) cancers. It is estimated that more than 1.5 million cases of cancer are diagnosed in the United States...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/20A61K38/21C07K14/535A61K38/19C07K14/54C07K14/56C12N15/67
CPCC07K14/535C07K14/5434C07K14/5443C07K14/56C12N2310/335A61K45/06A61K31/7105A61P35/00A61K31/7115A61K38/193A61K38/208A61K38/2086A61K38/212C12N15/102A61K2300/00A61K48/005A61K9/0019C12N15/67A61K39/3955A61K48/00
Inventor F·吉塞克U·萨欣D·G·威德沙因T·R·瓦格纳尔
Owner SANOFI SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com